Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Kidney cancer

IMPRINT: no survival benefit of IMA901 in RCC

Nature Reviews Nephrology volume 12, page 715 (2016)Cite this article

Subjects

The IMPRINT phase III trial shows that combination therapy with the multipeptide cancer vaccine IMA901 plus sunitinib does not improve the survival of patients with metastatic renal cell carcinoma (RCC) over sunitinib alone. In the trial, which included 339 HLA-A*02-positive patients with previously untreated metastatic or locally advanced clear cell RCC, median overall survival was 33.17 months in the sunitinib plus IMA901 group and was not reached (33.67–not reached) in the sunitinib monotherapy group. The researchers suggest that the magnitude of immune responses needs to be improved before the vaccine can be further developed for use in RCC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rini, B. I. et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet http://dx.doi.org/10.1016/S1470-2045(16)30408-9 (2016)

Download references

Authors
  1. Ellen F. Carney
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carney, E. IMPRINT: no survival benefit of IMA901 in RCC. Nat Rev Nephrol 12, 715 (2016). https://doi.org/10.1038/nrneph.2016.152

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneph.2016.152

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing